AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(33.33%)
USD 0.0
(33.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.32 Million USD | 45.02% |
| 2022 | -3.94 Million USD | 27.99% |
| 2021 | -13.16 Million USD | -21.86% |
| 2020 | -4.93 Million USD | 25.89% |
| 2019 | -6.5 Million USD | -29.38% |
| 2018 | -5.16 Million USD | -59.77% |
| 2017 | -3.14 Million USD | 16.29% |
| 2016 | -5.5 Million USD | 62.62% |
| 2015 | -10.04 Million USD | -1886.92% |
| 2014 | -505.72 Thousand USD | -538.39% |
| 2013 | -79.21 Thousand USD | -739.9% |
| 2012 | -9432.00 USD | -380.73% |
| 2011 | -1962.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -461.31 Thousand USD | -4981.64% |
| 2024 Q1 | -296.35 Thousand USD | 102.48% |
| 2023 FY | - USD | 45.02% |
| 2023 Q3 | -481.78 Thousand USD | 18.48% |
| 2023 Q4 | -647.18 Thousand USD | -34.33% |
| 2023 Q1 | -603.87 Thousand USD | 41.68% |
| 2023 Q2 | -590.97 Thousand USD | 2.14% |
| 2022 FY | - USD | 27.99% |
| 2022 Q2 | -953.87 Thousand USD | 7.04% |
| 2022 Q4 | -1.03 Million USD | 14.5% |
| 2022 Q1 | -1.02 Million USD | 12.79% |
| 2022 Q3 | -1.21 Million USD | -26.97% |
| 2021 Q3 | -2.51 Million USD | -79.52% |
| 2021 FY | - USD | -21.86% |
| 2021 Q1 | -771.39 Thousand USD | 64.37% |
| 2021 Q2 | -1.4 Million USD | -81.86% |
| 2021 Q4 | -1.17 Million USD | 53.28% |
| 2020 Q1 | -1.84 Million USD | -47.14% |
| 2020 Q4 | -2.16 Million USD | -70.83% |
| 2020 Q3 | -1.26 Million USD | -93.39% |
| 2020 FY | - USD | 25.89% |
| 2020 Q2 | -655.29 Thousand USD | 64.45% |
| 2019 Q1 | -2.28 Million USD | -217.01% |
| 2019 FY | - USD | -29.38% |
| 2019 Q4 | -1.25 Million USD | -12.48% |
| 2019 Q3 | -1.11 Million USD | 39.57% |
| 2019 Q2 | -1.84 Million USD | 19.5% |
| 2018 Q2 | -1.34 Million USD | 33.85% |
| 2018 Q1 | -2.02 Million USD | -93.01% |
| 2018 FY | - USD | -59.77% |
| 2018 Q4 | -722.27 Thousand USD | 22.75% |
| 2018 Q3 | -934.98 Thousand USD | 30.23% |
| 2017 Q2 | -436.41 Thousand USD | 7.91% |
| 2017 Q1 | -473.88 Thousand USD | 38.41% |
| 2017 FY | - USD | 16.29% |
| 2017 Q4 | -1.04 Million USD | 11.36% |
| 2017 Q3 | -1.18 Million USD | -171.35% |
| 2016 Q2 | -490.64 Thousand USD | 47.88% |
| 2016 Q4 | -769.38 Thousand USD | 50.51% |
| 2016 Q1 | -941.34 Thousand USD | 85.08% |
| 2016 FY | - USD | 62.62% |
| 2016 Q3 | -1.55 Million USD | -216.87% |
| 2015 Q3 | -1.69 Million USD | -8.38% |
| 2015 Q2 | -1.56 Million USD | -219.24% |
| 2015 FY | - USD | -1886.92% |
| 2015 Q1 | -488.81 Thousand USD | -50.22% |
| 2015 Q4 | -6.3 Million USD | -273.01% |
| 2014 Q2 | -44.76 Thousand USD | -642.62% |
| 2014 FY | - USD | -538.39% |
| 2014 Q4 | -325.4 Thousand USD | -154.33% |
| 2014 Q3 | -127.94 Thousand USD | -185.81% |
| 2014 Q1 | -6028.00 USD | 85.1% |
| 2013 Q4 | -40.46 Thousand USD | -1604.28% |
| 2013 Q2 | -27.29 Thousand USD | -722.85% |
| 2013 Q1 | -3317.00 USD | 77.63% |
| 2013 FY | - USD | -739.9% |
| 2013 Q3 | 2690.00 USD | 109.86% |
| 2012 Q1 | 740.00 USD | -38.64% |
| 2012 Q3 | 3650.00 USD | 261.74% |
| 2012 Q2 | 1009.00 USD | 36.35% |
| 2012 FY | - USD | -380.73% |
| 2012 Q4 | -14.83 Thousand USD | -506.33% |
| 2011 Q4 | 1206.00 USD | 130.24% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | -3988.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.729% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 60.805% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.377% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 86.622% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.471% |
| Mesoblast Limited | -62.38 Million USD | 96.275% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51.286% |
| Genus plc | 73.7 Million USD | 103.153% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 64.852% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 34.485% |
| Marizyme, Inc. | -34.28 Million USD | 93.221% |
| ContraFect Corporation | -64.99 Million USD | 96.425% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 73.509% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 48.658% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -65.773% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 12.125% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -348.574% |
| Accustem Sciences Inc. | -3.74 Million USD | 37.972% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 95.181% |
| EV Biologics, Inc. | -1.26 Million USD | -83.392% |
| Q BioMed Inc. | -617.62 Thousand USD | -276.249% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 165.057% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -267.457% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1.722% |
| Biomind Labs Inc. | -1.03 Million USD | -124.622% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 123.528% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 67.55% |
| Skye Bioscience, Inc. | -13.54 Million USD | 82.847% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -56.232% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9195.28% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 40.174% |
| IMV Inc. | -35.52 Million USD | 93.458% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.357% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 7.12% |
| GB Sciences, Inc. | -1.41 Million USD | -63.663% |
| Alpha Cognition Inc. | -9.7 Million USD | 76.057% |
| HST Global, Inc. | -5303.00 USD | -43720.856% |
| CSL Limited | 4.78 Billion USD | 100.049% |
| Halberd Corporation | -74.27 Thousand USD | -3028.502% |
| Enzolytics Inc. | -2.12 Million USD | -9.509% |
| Resverlogix Corp. | -11.74 Million USD | 80.209% |
| Affymax, Inc. | -14.29 Million USD | 83.744% |
| SYBLEU INC | -141.57 Thousand USD | -1541.452% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 24.133% |
| argenx SE | -216.02 Million USD | 98.924% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.801% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 290.947% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -55.034% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 713.398% |
| AVAX Technologies, Inc. | -6.11 Million USD | 61.983% |
| Zenith Capital Corp. | -8.6 Million USD | 72.998% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.066% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13239.188% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 5.013% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1220.17% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 94.137% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 19.656% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -122.096% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 34660.083% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -32.79% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -20.975% |
| BioStem Technologies, Inc. | -7.55 Million USD | 69.236% |
| ONE Bio Corp. | 13.61 Million USD | 117.071% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1183.255% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -12.971% |
| Agentix Corp. | -1.37 Million USD | -69.405% |
| LadRx Corporation | 412.28 Thousand USD | 663.647% |
| Cell Source, Inc. | -4.27 Million USD | 45.61% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -532.812% |
| Regen BioPharma, Inc. | 1.46 Million USD | 258.519% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -148.02% |
| NovAccess Global Inc. | -1.03 Million USD | -124.568% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 126.247% |
| Itoco Inc. | -1.86 Million USD | -24.335% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -512.144% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -108.228% |
| Kadimastem Ltd | -2.62 Million USD | 11.453% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -871.7% |
| CytoDyn Inc. | -18.02 Million USD | 87.111% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2840.465% |
| Mobile Lads Corp. | -2.24 Million USD | -3.688% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -18902.535% |
| Qrons Inc. | -40.08 Thousand USD | -5697.809% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -378.469% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 540.591% |
| Rebus Holdings, Inc. | -951 Thousand USD | -144.355% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -118.813% |
| International Stem Cell Corporation | 202 Thousand USD | 1250.406% |
| Bioxytran, Inc. | -3.82 Million USD | 39.169% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4314.552% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 5.61% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.521% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5064.044% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 15.127% |
| Neutra Corp. | -181.24 Thousand USD | -1182.129% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 88.473% |
| PureTech Health plc | -11.62 Million USD | 80.014% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 88.472% |
| IXICO plc | -707 Thousand USD | -228.687% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 69.762% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 95.193% |
| CSL Limited | 4.73 Billion USD | 100.049% |
| Cellectis S.A. | -92.63 Million USD | 97.491% |